Prelude Therapeutics
PRLD Small CapHealthcare · Biotechnology
Mis à jour: Jun 18, 2026, 22:21 UTC
Price Chart
Indicateurs clés
Valuation Analysis
About the Company
Prelude Therapeutics en bref
Prelude Therapeutics (PRLD) is currently trading at 3,77 € with a market capitalization of 300 M €. The 52-week range spans from 0,65 € to 4,83 €; the current price is 22% below the yearly high.
💰 Dividende
Prelude Therapeutics currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Avis des analystes
3 analystes évaluent Prelude Therapeutics (PRLD) au consensus : Achat Fort. L'objectif de cours moyen est de 6,98 €, soit un potentiel de +85.19% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 5,24 € à 8,73 €.
Prelude Therapeutics : la thèse d'investissement en détail
Prelude Therapeutics (PRLD) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
Le scénario haussier
With a gross margin near 100%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Wall Street consensus sits at Strong Buy with an average price target implying roughly 85.19% upside from current levels — analyst sentiment is firmly constructive.
À surveiller
- The analyst consensus price target implies 85.19% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.
Thèse d'investissement : forces et faiblesses
- Marge brute élevée de 100% — signe d'un pouvoir de fixation des prix
- Consensus des analystes : Strong Buy
- Bilan solide avec faible endettement (D/E 29.45)
- –Free cash flow négatif
Aperçu technique
Price shows short-term weakness (below 50d MA) but is still in a longer-term uptrend (above 200d MA).
Profil de risque
The data points to market-like volatility, elevated short interest (6.73%).
Trading Data
Related Stocks in the Same Sector
More Santé stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Prelude Therapeutics?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news
